Primary cutaneous follicle center lymphoma is a rare type of blood cancer that appears on the skin and requires careful medical management. While this condition typically grows slowly and has a positive outlook, understanding treatment options — both standard approaches and those being tested in clinical trials — can help patients and their families navigate care decisions with greater confidence.

Understanding Your Treatment Path

When you receive a diagnosis of follicle center lymphoma that affects the skin, the main goal of treatment is to control the disease, reduce visible skin changes, and help you maintain a good quality of life. Unlike some other types of lymphoma, primary cutaneous follicle center lymphoma stays in the skin and does not involve other organs at the time of diagnosis. This makes a significant difference in how doctors approach treatment.^[1]

Treatment choices depend on several important factors. Your healthcare team will consider where the lumps or patches are located on your body, how many skin areas are affected, and whether you have just one spot or multiple lesions spread across different body regions. The location matters because tumors on the head or trunk generally respond better to treatment than those on the legs. Your age, overall health, and personal preferences also play a role in deciding which treatment approach makes the most sense for you.^[1][3]

This type of lymphoma is classified as indolent, which means it grows slowly. Because of this, some patients with very limited disease and no bothersome symptoms might not need immediate treatment. Instead, doctors may recommend careful monitoring, known as watchful waiting or active surveillance. During this time, you will have regular check-ups to make sure the disease is not getting worse. Treatment begins when symptoms appear or when the disease starts to spread.^[9]

Medical guidelines recognize that primary cutaneous follicle center lymphoma behaves differently from similar-looking lymphomas that start in lymph nodes or inside the body. For this reason, the treatment recommendations are specifically tailored to skin lymphomas. Approved treatments are based on years of clinical experience and research showing what works best for patients with this condition. At the same time, researchers continue to explore new therapies in clinical trials, hoping to improve outcomes even further.^[1][3]

Standard Treatment Approaches

The foundation of treating primary cutaneous follicle center lymphoma involves several well-established methods. The choice of treatment depends primarily on whether you have a single skin lesion or multiple areas of involvement.^[9]

Radiation Therapy

Radiation therapy is one of the most effective treatments for this type of lymphoma, especially when only one or a few areas of skin are affected. This approach uses targeted beams of energy to destroy cancer cells in the treated area. Doctors typically use a type called superficial radiation therapy or electron beam therapy, which delivers radiation to the skin surface without deeply penetrating into the body.^[13]

The treatment is usually given in multiple sessions, called fractions, over several weeks. Each session lasts only a few minutes, and the procedure itself is painless. The total dose of radiation is measured in units called Gray (Gy) or centigray (cGy). For primary cutaneous follicle center lymphoma, doctors commonly deliver between 1,400 to 4,000 cGy, depending on the size and location of the tumor. This careful dosing helps kill cancer cells while protecting healthy surrounding tissue.^[13]

Radiation therapy works very well for localized disease. Studies show that many patients achieve complete clearing of their skin lesions after radiation. About half of patients treated with radiation for early-stage disease remain cancer-free for many years. However, it’s important to know that the lymphoma can come back in other areas of the skin in about 30 to 40 percent of cases. When this happens, additional treatment may be needed.^[12][13]

Side effects from radiation are usually limited to the treated skin area. You might notice redness, dryness, or changes in skin color that look like a sunburn. These effects typically heal within a few weeks after treatment ends. In some cases, the treated skin may remain slightly darker or lighter than the surrounding area. Hair loss can occur in the treated area if radiation is given to the scalp, and this hair may not always grow back.^[13]

Surgical Removal

For patients with a single, small lesion, surgical excision — meaning cutting out the tumor — can be an effective treatment option. This is a relatively simple procedure done under local anesthesia, where the doctor removes the visible tumor along with a small margin of normal-looking skin around it to make sure all cancer cells are taken out.^[9]

Surgery offers the advantage of providing both treatment and a tissue sample for detailed examination under the microscope. This helps confirm the diagnosis and check that the entire tumor has been removed. The success rate is good, with many patients experiencing complete clearing of the lesion. However, similar to radiation therapy, there is about a 60 percent chance that new lesions may appear elsewhere on the skin over time. When this happens, additional treatment with radiation or other methods may be necessary.^[14]

The main side effects of surgery are those common to any surgical procedure: pain at the site, potential infection, bleeding, and a scar. The size of the scar depends on the size of the tumor removed. For tumors on visible areas like the face or scalp, some patients may have cosmetic concerns about scarring.^[9]

Systemic Medications

When the lymphoma affects multiple areas of the skin or when local treatments like surgery or radiation are not practical, doctors may recommend medications that work throughout the entire body. These are called systemic therapies.^[9]

Rituximab is a medication that specifically targets B cells, the type of cells that become cancerous in this lymphoma. Rituximab is a laboratory-made protein called a monoclonal antibody that attaches to a marker called CD20 on the surface of B cells. This attachment signals the immune system to destroy these cells. Rituximab can be given alone or combined with other medications.^[14]

When used by itself, rituximab is typically given through a vein (intravenously) once a week for four weeks, then repeated after a break. Studies have shown that rituximab monotherapy leads to complete clearing of skin lesions in many patients. About 67 percent of patients treated with rituximab alone may experience a return of the lymphoma over time, but when it does come back, it usually responds well to additional treatment.^[14]

Common side effects of rituximab include reactions during the infusion, such as fever, chills, rash, or feeling unwell. These reactions are usually mild and occur most often during the first infusion. Rituximab can also lower the number of white blood cells temporarily, which increases the risk of infections. For this reason, patients receiving rituximab should be careful to avoid people who are sick and report any signs of infection to their doctor right away.^[14]

For more widespread or aggressive disease, doctors may recommend chemoimmunotherapy, which combines chemotherapy drugs with rituximab. Common chemotherapy regimens include combinations with names like R-CVP or R-CHOP (the “R” stands for rituximab). These combinations use several drugs that work together to kill cancer cells more effectively than any single drug alone. Chemoimmunotherapy has a lower relapse rate compared to other treatments, with only about 20 percent of patients experiencing a return of the lymphoma within the first five years. This makes it a strong option for patients who need more intensive treatment.^[14]

The duration of treatment varies depending on which approach is used. Radiation therapy typically takes several weeks of daily sessions. Surgery is a one-time procedure, though healing takes a few weeks. Systemic medications like rituximab may be given over several months, with regular monitoring continuing for years afterward to watch for any signs of the lymphoma returning.^[13][14]

Other Skin-Directed Therapies

For some patients, especially those with small or superficial lesions, doctors may use treatments applied directly to the skin. These are less common but can be helpful in certain situations. Options include applying corticosteroid creams or injecting steroids directly into the tumor. Another option is using extreme cold to freeze and destroy abnormal cells, a technique called cryotherapy. About 33 percent of patients treated with steroid injections experience a return of their lymphoma, but these approaches avoid the side effects associated with radiation or systemic medications.^[9][12]

Emerging Treatments in Clinical Trials

While standard treatments work well for many patients, researchers continue to search for better therapies that might work more effectively, cause fewer side effects, or prevent the lymphoma from coming back. Clinical trials are research studies where new treatments are carefully tested in patients to see if they are safe and whether they work better than existing options.^[14]

Clinical trials happen in different phases, each with a specific purpose. Phase I trials test a new treatment in a small group of people to find the safest dose and identify side effects. Phase II trials give the treatment to more people to see if it is effective and to further study its safety. Phase III trials compare the new treatment with the current standard treatment to see which one works better. Larger groups of patients participate in Phase III trials, and these studies provide the strongest evidence about whether a new treatment should become a standard option.^[14]

New Immunotherapy Approaches

Because primary cutaneous follicle center lymphoma involves B cells, many new treatments focus on ways to target these cells more precisely or to help the immune system recognize and destroy them. One area of research involves developing new monoclonal antibodies similar to rituximab but designed to work in different ways or to have fewer side effects. These newer antibodies might attach to different markers on B cells or might trigger a stronger immune response against the cancer.^[14]

Another promising approach being studied in clinical trials involves medications that interfere with signals cancer cells need to survive and multiply. Some of these are small molecules that can enter cells and block specific proteins or pathways that the lymphoma cells depend on. By stopping these signals, the drugs can cause cancer cells to stop growing or die without affecting normal cells as much as traditional chemotherapy does.^[14]

Targeted Therapy

Scientists have learned that certain genetic changes occur in the cells of primary cutaneous follicle center lymphoma. In about 85 percent of cases, there is a specific change called a BCL-2 rearrangement, where a gene moves from its normal location to a new spot on a different chromosome. This change causes the cell to make too much of a protein that prevents cell death, allowing the cancer cells to live longer than they should. Researchers are testing drugs that specifically block this BCL-2 protein, helping cancer cells die naturally as they are supposed to.^[1]

Although BCL-2 inhibitors are already approved for treating some other types of lymphoma, they are still being studied in clinical trials for primary cutaneous follicle center lymphoma. Early results from these studies suggest these medications may help shrink tumors and prevent the disease from progressing. Trials are ongoing to determine the best dose, how long treatment should last, and whether combining BCL-2 inhibitors with other drugs works better than using them alone.^[14]

Modified Radiation Techniques

Researchers are also exploring ways to make radiation therapy more effective while reducing side effects. Some clinical trials are testing different radiation doses or schedules to find the optimal balance between killing cancer cells and protecting healthy skin. Others are studying whether adding medications to radiation therapy can improve results.^[13]

Participating in Clinical Trials

Clinical trials are available in many locations, including major cancer centers in the United States, Europe, and other regions around the world. Not every patient is eligible for every trial. Eligibility depends on factors such as the stage of your disease, what treatments you have received in the past, your overall health, and sometimes specific genetic features of your lymphoma.^[14]

If you are interested in joining a clinical trial, talk with your doctor. They can help you understand which trials might be appropriate for you and explain the potential benefits and risks. Participating in a clinical trial gives you access to new treatments that are not yet widely available, and you contribute to research that may help future patients. However, new treatments may have unknown side effects, and there is no guarantee that an experimental treatment will work better than standard options.^[14]

Most Common Treatment Methods

• Radiation Therapy
  • Superficial radiation or electron beam therapy targeted to affected skin areas
  • Delivered in multiple sessions over several weeks
  • Total doses typically range from 1,400 to 4,000 cGy
  • Very effective for localized disease with complete clearing in many patients
  • Side effects limited to treated skin, including redness and dryness
• Surgical Excision
  • Removal of single, small lesions under local anesthesia
  • Includes removal of a margin of normal skin around the tumor
  • About 60 percent risk of new lesions appearing elsewhere over time
  • Common side effects include scarring, pain, and risk of infection
• Rituximab Monotherapy
  • Monoclonal antibody that targets CD20 marker on B cells
  • Given intravenously, typically once weekly for four weeks
  • Effective in achieving complete clearing of skin lesions
  • About 67 percent of patients may experience relapse over time
  • Side effects include infusion reactions and increased infection risk
• Chemoimmunotherapy
  • Combination of chemotherapy drugs with rituximab
  • Common regimens include R-CVP or R-CHOP
  • Lowest relapse rate, with about 20 percent relapsing within five years
  • Side effects include hair loss, nausea, fatigue, and blood count changes
• Watchful Waiting
  • Active surveillance with regular check-ups
  • Appropriate for patients with limited disease and no symptoms
  • Treatment begins when symptoms develop or disease progresses
  • Avoids side effects of active treatment
• Skin-Directed Therapies
  • Topical corticosteroid creams
  • Intralesional steroid injections
  • Cryotherapy (freezing abnormal cells)
  • About 33 percent relapse rate with steroid injections
  • Fewer systemic side effects compared to other treatments